International Therapeutics – Brief Article

International Therapeutics – Brief Article – Statistical Data Included

Drug discovery and development company International Therapeutics Inc. of Seattle has landed more than $2 million in Series B financing from private investors. Proceeds from the funding are expected to fuel development and human trials for the company’s lead HIV-fighting compound. The three-year-old company also announced the appointment of two new board members: Dr. Michael Kahn, a principle scientist at Seattle’s Pacific Northwest Research Institute, and Dr. H. Perry Fell, founder and chief scientific officer of Seattle Genetics. www.TheDeal.com

COPYRIGHT 2001 The Deal LLC

COPYRIGHT 2001 Gale Group